Cargando…

Dibenzofuranylethylamines as 5-HT(2A/2C) Receptor Agonists

[Image: see text] The human 5-HT(2) receptor subtypes have high sequence identity in their orthosteric ligand-binding domain, and many agonists are poorly selective between the 5-HT(2A) and 5-HT(2C) subtypes. Nevertheless, their activation is associated with different pharmacological outcomes. We sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Yempala, Thirumal, Brea, José, Loza, María Isabel, Matthies, Douglas J., Zapata-Torres, Gerald, Cassels, Bruce K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016908/
https://www.ncbi.nlm.nih.gov/pubmed/32064387
http://dx.doi.org/10.1021/acsomega.9b03430
_version_ 1783497083609677824
author Yempala, Thirumal
Brea, José
Loza, María Isabel
Matthies, Douglas J.
Zapata-Torres, Gerald
Cassels, Bruce K.
author_facet Yempala, Thirumal
Brea, José
Loza, María Isabel
Matthies, Douglas J.
Zapata-Torres, Gerald
Cassels, Bruce K.
author_sort Yempala, Thirumal
collection PubMed
description [Image: see text] The human 5-HT(2) receptor subtypes have high sequence identity in their orthosteric ligand-binding domain, and many agonists are poorly selective between the 5-HT(2A) and 5-HT(2C) subtypes. Nevertheless, their activation is associated with different pharmacological outcomes. We synthesized five phenethylamine analogs in which the benzene ring is replaced by a bulky dibenzo[b,d]furan moiety and found a couple with >70-fold 5-HT(2C) selectivity. Molecular docking studies of the most potent compound (5) at both receptor subtypes revealed the likely structural basis of its selectivity. Although in both cases, some crucial interactions are conserved, the change of the Ala222(5.46) residue in the 5-HT(2C) receptor to the larger Ser242(5.46) in the 5-HT(2A) subtype, which is the only structural difference between the orthosteric binding pockets of both receptors, weakens a π–π stacking interaction between the dibenzofuran moiety and the important Phe(6.52) residue and breaks a hydrogen bond between the dibenzofuran oxygen and Ser(5.43), explaining the selectivity of compound 5 for the 5-HT(2C) receptor. We believe that this effect of the residue at position 5.46 merits further exploration in the search for selective 5-HT(2C) receptor agonists that are of considerable interest in the treatment of schizophrenia and substance abuse.
format Online
Article
Text
id pubmed-7016908
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-70169082020-02-14 Dibenzofuranylethylamines as 5-HT(2A/2C) Receptor Agonists Yempala, Thirumal Brea, José Loza, María Isabel Matthies, Douglas J. Zapata-Torres, Gerald Cassels, Bruce K. ACS Omega [Image: see text] The human 5-HT(2) receptor subtypes have high sequence identity in their orthosteric ligand-binding domain, and many agonists are poorly selective between the 5-HT(2A) and 5-HT(2C) subtypes. Nevertheless, their activation is associated with different pharmacological outcomes. We synthesized five phenethylamine analogs in which the benzene ring is replaced by a bulky dibenzo[b,d]furan moiety and found a couple with >70-fold 5-HT(2C) selectivity. Molecular docking studies of the most potent compound (5) at both receptor subtypes revealed the likely structural basis of its selectivity. Although in both cases, some crucial interactions are conserved, the change of the Ala222(5.46) residue in the 5-HT(2C) receptor to the larger Ser242(5.46) in the 5-HT(2A) subtype, which is the only structural difference between the orthosteric binding pockets of both receptors, weakens a π–π stacking interaction between the dibenzofuran moiety and the important Phe(6.52) residue and breaks a hydrogen bond between the dibenzofuran oxygen and Ser(5.43), explaining the selectivity of compound 5 for the 5-HT(2C) receptor. We believe that this effect of the residue at position 5.46 merits further exploration in the search for selective 5-HT(2C) receptor agonists that are of considerable interest in the treatment of schizophrenia and substance abuse. American Chemical Society 2020-01-27 /pmc/articles/PMC7016908/ /pubmed/32064387 http://dx.doi.org/10.1021/acsomega.9b03430 Text en Copyright © 2020 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Yempala, Thirumal
Brea, José
Loza, María Isabel
Matthies, Douglas J.
Zapata-Torres, Gerald
Cassels, Bruce K.
Dibenzofuranylethylamines as 5-HT(2A/2C) Receptor Agonists
title Dibenzofuranylethylamines as 5-HT(2A/2C) Receptor Agonists
title_full Dibenzofuranylethylamines as 5-HT(2A/2C) Receptor Agonists
title_fullStr Dibenzofuranylethylamines as 5-HT(2A/2C) Receptor Agonists
title_full_unstemmed Dibenzofuranylethylamines as 5-HT(2A/2C) Receptor Agonists
title_short Dibenzofuranylethylamines as 5-HT(2A/2C) Receptor Agonists
title_sort dibenzofuranylethylamines as 5-ht(2a/2c) receptor agonists
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016908/
https://www.ncbi.nlm.nih.gov/pubmed/32064387
http://dx.doi.org/10.1021/acsomega.9b03430
work_keys_str_mv AT yempalathirumal dibenzofuranylethylaminesas5ht2a2creceptoragonists
AT breajose dibenzofuranylethylaminesas5ht2a2creceptoragonists
AT lozamariaisabel dibenzofuranylethylaminesas5ht2a2creceptoragonists
AT matthiesdouglasj dibenzofuranylethylaminesas5ht2a2creceptoragonists
AT zapatatorresgerald dibenzofuranylethylaminesas5ht2a2creceptoragonists
AT casselsbrucek dibenzofuranylethylaminesas5ht2a2creceptoragonists